Prognostic

  • Evaluate 18F-16β-fluoro-5α-dihydrotestosterone and fludeoxyglucose positron emission tomography as prognostic biomarkers for patients treated with abiraterone acetate. (Abstract 56)
  • Investigate the role of interleukin-23 as a biomarker in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling. (Abstract 142)
  • Explore AXIN2 as a potential biomarker for prostate cancer recurrence after radical prostatectomy. (Abstract 145)
  • Examine the potential of tissue microarrays for defining and validating new biomarkers in urological oncology, which are then linked to clinical databases containing clinical outcome data. (Abstract 181)
  • Validate exosomal microRNA as prognostic biomarkers using blood-based nucleic acid assays in mCRPC. (Abstract 260)
  • Determine a new biomarker to detect which patients with small volume prostate cancers will develop PSA failure following radical prostatectomy (Abstract 279)

Prognostic and Therapeutic

  • Assess plasma methylated glutathione s-transferase 1 as a potential prognostic marker in CRPC and conduct a phase 3 trial as a potential surrogate therapeutic efficacy marker for cytotoxic chemotherapy. (Abstract 11)
  • Explore innovative methodology to detect ARv567es, found in CTC-enriched peripheral blood samples from patients with CRPC, as a prognostic and therapeutic biomarker, allowing more appropriate treatment selection. (Abstract 112)

Clinical Outcomes


Continue Reading

  • Characterize the relationship between PSA kinetics and overall survival and establish exposure response in chemotherapy-naïve and -pretreated patients with mCRPC following abiraterone acetate administration using a sequential exposure-biomarker-survival modeling analysis. (Abstract 39)
  • Determine if circulating microRNAs can be used as biomarkers to predict docetaxel chemotherapy outcome in CRPC and stratify patients for clinical trials. (Abstract 44)
  • Validate role of assays as biomarkers in sequential monitoring and characterization of CTCs in patients with mCRPC treated with recently approved therapeutics. (Abstract 78)
  • Characterize sipuleucel-T mechanisms of action to identify posttreatment biomarkers of clinical outcome. (Abstract 88)
  • Identify small subsets of patients with mCRPC that “may benefit from targeted agents approved for other solid tumors (imatinib, cetuximab), promising therapies in clinical trials (cabozantinib) or agents not routinely used for prostate cancer (gemcitabine)” using tumor molecular profiling as biomarkers of drug response. (Abstract 107)
  • Characterize biomarkers that significantly correlate with greater immune response to sipuleucel-T for mCRPC. (Abstract 219)
  • Measure tumor burden in bone as a response biomarker in patients with mCRPC being treated with abiraterone acetate using the Bone Scan Index (BSI). “Calculation of BSI could be a valuable tool for treatment response evaluation as a complement to the traditional methods.” (Abstract 244)
  • Identify novel CTC candidates in blood as biomarkers from patients with mCRPC. (Abstract 209)

The Biomarkers Consortium, managed by the Foundation for the National Institutes of Health, will launch a project for clinical validation of novel technologies for evaluating CTCs in May 2014.7

References

  1. American Cancer Society. Cancer facts and figures 2014. Atlanta, GA: American Cancer Society; 2014:4, 18-19, 51. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed March 12, 2014.
  2. National Cancer Institute. NCI Dictionary of Cancer Terms. Biomarker. http://www.cancer.gov/dictionary?cdrid=45618. Accessed February 19, 2014.
  3. Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010;1:150-177.
  4. Schiffer E. Biomarkers for prostate cancer. World J Urol. 2007;25(3):557-562.
  5. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Nat Genet. 2013;45(4):385-391, 391e1-2.
  6. ASCO University. Meeting library. http://meetinglibrary.asco.org/. Accessed March 12, 2014.
  7. The Biomarkers Consortium. Pipeline projects. Clinical validation of novel technologies for evaluating circulating tumor cells. http://www.biomarkersconsortium.org/projects_pipeline.php. Accessed February 20, 2014.